JAMA Dermatology · 2015 · 61 citations · 5 references
MedicineDermatologyOphthalmologyCutaneous OncologyDermatopathologyImmunotherapyCutaneous Metastatic DiseaseGranulomatous DermatitisGranulomatous DermatosesInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersChronic Granulomatous DiseaseCutaneous Drug EruptionsCutaneous ImmunologyGranulomatous EruptionsGranulomatous Skin InflammationPembrolizumab TherapyPsoriasiform DermatitisXanthogranulomatous Dermatoses
At a 12-week follow-up appointment, a dramatic improvement in the appearance of the cutaneous lesions was noted, with near complete resolution of the patches and plaques and small residual foci at the prior larger nodular areas. The patient continued topical nitrogen mustard with continued improvement over 12 additional weeks (Figure However, the patient subsequently developed ophthalmic symptoms, including vertical and abduction defects, blurred vision, and peripheral vision loss, attributed to ocular involvement of the NXG. The patient then began dexamethasone 20-mg doses twice a week and cyclophosphamide 300-mg/m 2 doses on days 1, 8, and 15 of a 28-day cycle. He has shown clinical and laboratory improvement after 6 months.
5
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud et al. · JAMA Dermatology · 2015 · 452 citations · Full text
Medicine, Oncology, Pharmacology +15